A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Summary

This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Timeline

Start

2022-01-26

Primary completion

2024-12-31

Completion

2025-07-01

Publications

• Cao L, Zhou M, Wei Z, Zhu R, Chen H, Zhou L, Hu S, Bai Z, Wu S. Frontline therapy combining with intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome in pediatric relapsed B-ALL receiving pCAR-19B-cases report. BMC Pediatr. 2025 Oct 2;25(1):738. doi: 10.1186/s12887-025-06118-1.

Drugs

Indications